GILD Gilead Sciences, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

GILD [NASD]

Gilead Sciences, Inc.

Healthcare | Drug Manufacturers - General | USA

statements

Index	S&P 500	P/E	-	EPS (ttm)	-0.24	Insider Own	0.41%	Shs Outstand	1.26B	Perf Week	-1.95%
Market Cap	77.39B	Forward P/E	8.71	EPS next Y	6.98	Insider Trans	-0.59%	Shs Float	1.25B	Perf Month	-2.35%
Income	-257.00M	PEG	-	EPS next Q	1.96	Inst Own	81.50%	Short Float	1.55%	Perf Quarter	-18.45%
Sales	22.17B	P/S	3.49	EPS this Y	1.10%	Inst Trans	0.12%	Short Ratio	2.10	Perf Half Y	-23.92%
Book/sh	14.36	P/B	4.23	EPS next Y	-0.14%	ROA	-0.40%	Target Price	78.42	Perf Year	-7.89%
Cash/sh	14.86	P/C	4.09	EPS next 5Y	0.59%	ROE	-1.20%	52W Range	59.65 - 85.97	Perf YTD	-6.45%
Dividend	2.72	P/FCF	14.96	EPS past 5Y	-10.50%	ROI	9.50%	52W High	-29.29%	Beta	0.52
Dividend %	4.47%	Quick Ratio	2.20	Sales past 5Y	-2.00%	Gross Margin	78.60%	52W Low	1.91%	ATR	1.35
Employees	11800	Current Ratio	2.30	Sales Q/Q	-9.50%	Oper. Margin	-4.30%	RSI (14)	37.71	Volatility	2.54% 1.94%
Optionable	Yes	Debt/Eq	1.34	EPS Q/Q	-280.70%	Profit Margin	-1.20%	Rel Volume	3.34	Prev Close	60.67
Shortable	Yes	LT Debt/Eq	1.17	Earnings	Oct 28 AMC	Payout	-	Avg Volume	9.24M	Price	60.79
Recom	2.50	SMA20	-2.90%	SMA50	-5.73%	SMA200	-14.53%	Volume	30,847,899	Change	0.20%

Sep-30-20

Resumed

Jefferies

Buy

$78

Sep-15-20

Upgrade

Maxim Group

Hold → Buy

$88

Jul-31-20

Reiterated

Wells Fargo

Equal Weight

$87 → $76

Jul-31-20

Reiterated

SunTrust

Hold

$73 → $74

Jul-31-20

Reiterated

RBC Capital Mkts

Outperform

$89 → $87

Jul-31-20

Reiterated

Piper Sandler

Overweight

$90 → $85

Jul-31-20

Reiterated

Morgan Stanley

Equal-Weight

$80 → $79

Jul-31-20

Reiterated

Credit Suisse

Neutral

$75 → $73

Jul-20-20

Upgrade

Credit Suisse

Underperform → Neutral

$64 → $75

Jun-03-20

Upgrade

SVB Leerink

Mkt Perform → Outperform

$85 → $94

May-26-20

Upgrade

SunTrust

Sell → Hold

$73

May-01-20

Downgrade

SunTrust

Hold → Sell

$70

May-01-20

Downgrade

Raymond James

Outperform → Mkt Perform

May-01-20

Downgrade

JP Morgan

Overweight → Neutral

Apr-27-20

Downgrade

UBS

Buy → Neutral

$77 → $80

Apr-20-20

Downgrade

Wells Fargo

Overweight → Equal Weight

$87

Apr-20-20

Downgrade

BMO Capital Markets

Outperform → Market Perform

$79

Apr-17-20

Downgrade

CFRA

Hold → Sell

Mar-31-20

Initiated

Wolfe Research

Peer Perform

Mar-20-20

Upgrade

Piper Sandler

Neutral → Overweight

$70 → $90

Oct-23-20 04:33PM	Remdesivir is not a knock out punch but it does help patients recover quicker: doctor Yahoo Finance Video
03:30PM	Pharmaceutical companies are doing a good job with efficacy and transparency: physician Yahoo Finance Video
03:24PM	Stock Market Today With Jim Cramer: Don't Buy Gilead On FDA News TheStreet.com
03:04PM	Doctor on COVID-19 spike: We need to be worried Yahoo Finance Video
01:42PM	Dow Jones Leads Market Declines As Intel, American Express Fall On Earnings Investor's Business Daily
01:19PM	Werner, Carlisle, Gilead, Intel and Mattel as Zacks Bull and Bear of the Day Zacks
01:07PM	US STOCKS-Wall Street slips as stimulus deadlock weighs Reuters
12:31PM	Gilead Analyst: FDA's Remdesivir Label A Best Case Scenario For Biopharma Benzinga
12:30PM	Shares of Gilead rise after FDA formally approves Remdesivir Yahoo Finance Video
11:47AM	Gilead Sciences Closes Immunomedics Purchase TheStreet.com
11:38AM	US STOCKS-Wall Street subdued as wait for stimulus continues Reuters
11:33AM	Coronavirus update: US sets new daily case record; FDA approves Gilead's remdesivir Yahoo Finance
11:25AM	Doctors question FDA approval of Gileads COVID-19 treatment and say it has limited benefits MarketWatch
10:06AM	Dow Jones Today, Stocks Mixed As Banks Rally, Coronavirus Stimulus Talks Lag And Intel Tumbles Investor's Business Daily
10:05AM	Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus Zacks
10:02AM	Remdesivirs Approval for Covid Doesn't Erase Doubts Bloomberg
10:01AM	Remdesivir Gets FDA Approval. What It Means for Gilead Stock and Vaccine Makers. Barrons.com
09:57AM	ROCE Insights For Gilead Sciences Benzinga
09:44AM	COVID-19 'Pool testing' in schools would give insight on how well masks in schools are doing: Dr. Dara Kass Yahoo Finance Video
09:15AM	Gilead Sciences Completes Acquisition of Immunomedics, Inc. Business Wire
09:00AM	Why Gilead Sciences Stock Is on the Move Today Motley Fool
07:42AM	Will Coronavirus Woes Affect Gilead's (GILD) Q3 Earnings? Zacks
07:09AM	Intel, Gilead, American Express, Wells Fargo - 5 Things You Must Know Friday TheStreet.com
06:38AM	Gilead shares rise after United States approves remdesivir as COVID-19 drug Reuters
06:21AM	Coronavirus tally: Global cases of COVID-19 41.8 million, 1.14 million deaths and FDA approves remdesivir as treatment MarketWatch
05:24AM	Gileads Covid-19 Remdesivir Drug Scores FDA Approval; Shares Surge SmarterAnalyst
04:42AM	Gileads Remdesivir Becomes First Virus Treatment to Win FDA Nod Bloomberg
Oct-22-20 09:58PM	Gilead's Remdesivir First Drug to Win FDA Approval for Coronavirus Motley Fool
05:52PM	Stimulus or No? Plus News from GILD, Earnings from INTC & MAT Zacks
05:35PM	Gilead Sciences Gets FDA Approval For Covid-19 Treatment Remdesivir Investor's Business Daily
04:56PM	Gilead Covid-19 Drug Remdesivir Cleared by FDA TheStreet.com
04:46PM	FDA Approves Remdesivir for Treating Coronavirus Patients Barrons.com
04:42PM	FDA Approves Gilead's Remdesivir For Treatment Of Hospitalized COVID-19 Patients Benzinga
04:37PM	Gilead's stock rises as FDA formally approves remdesivir MarketWatch
04:34PM	US STOCKS-Wall Street closes higher, trade choppy as U.S. stimulus talks eyed Reuters
04:31PM	Stock Market Today: Stimulus' Siren Song Pulls the Bulls Along Kiplinger
04:22PM	Gileads Sales Will Slip Even With Remdesivir Barrons.com
04:02PM	U.S. Food and Drug Administration Approves Gileads Antiviral Veklury® (remdesivir) for Treatment of COVID-19 Business Wire
12:15PM	Anthony Welters Joins Gilead Sciences Board of Directors Business Wire
11:22AM	Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates Zacks
10:15AM	Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus Zacks
10:14AM	Multi-Camera MIPI Switch from Diodes Incorporated Enables Smaller Product Profiles Business Wire
Oct-21-20 05:58PM	CRISPR Therapeutics Reports Mixed Cancer Trial Results Motley Fool
12:32PM	Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth Zacks
12:00PM	Fauci Tells Doctors Covid is Worse in the U.S. Because of a Failure to Avoid Crowds Barrons.com
10:37AM	Dozens of volunteers to be deliberately infected with COVID-19 in effort to speed up vaccine development MarketWatch
07:44AM	Will Lilly (LLY) Witness Recovery in Sales in Q3 Earnings? Zacks
07:01AM	Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans Business Wire
06:09AM	Better Buy: Moderna vs. Gilead Sciences Motley Fool
Oct-20-20 05:45PM	Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
02:55PM	Were Hedge Funds Right About Souring On Gilead Sciences, Inc. (GILD)? Insider Monkey
02:11PM	Covid-19 Vaccines Could Take a Critical Next Step in November Just Not In Time for the Election Barrons.com
09:02AM	Gilead Coronavirus Drug Treated President But Is GILD Stock A Buy? Investor's Business Daily
08:00AM	Is Gilead Sciences a Good Coronavirus Stock? Motley Fool
05:30AM	Gilead Stands Up for Its Covid and HIV Drugs Barrons.com
02:30AM	UK launches world's first human challenge trial for COVID-19 with Irish company hVivo Yahoo Finance
Oct-19-20 04:32PM	The most difficult phase of the epidemic is ahead of us: doctor Yahoo Finance Video
02:40PM	'Not just him': What Trump's antibody use says about the future of coronavirus treatments Yahoo Finance
01:35PM	Gilead's (GILD) CAR T Cell Therapy Gets Positive CHMP Opinion Zacks
11:00AM	Can Gilead Make Money From Its COVID-19 Treatment Remdesivir? Motley Fool
08:30AM	Gilead Presents New Data from Antiviral Development Programs at IDWeek 2020 Business Wire
Oct-18-20 06:42AM	Does This Metric Tell Investors All They Need to Know About Gilead Sciences? Motley Fool
Oct-17-20 03:57AM	Gilead Sciences, Inc. -- Moody's affirms Gilead at A3; outlook revised to negative Moody's
Oct-16-20 03:38PM	I think were at the beginning of a third surge of coronavirus: Advancing Health Equity CEO Yahoo Finance Video
03:36PM	Coronavirus Latest: Friday, October 16 Yahoo Finance Video
03:24PM	Misinformation is the 'biggest concern' leading up to election: CrowdStrike President Yahoo Finance Video
01:53PM	Can Cytonics Pivot Successfully to Covid-19 Therapeutics? InvestorPlace
01:25PM	WHO Questions Effectiveness of Remdesivir on Covid-19 Death Rates Barrons.com
11:22AM	Gloomy COVID drug data shows why big, randomised trials matter Reuters
11:04AM	Coronavirus update: Global COVID-19 cases top 38.9 million as trial of promising therapy finds it does not stop patients dying MarketWatch
09:56AM	WHO: Remdesivir Does Not Substantially Affect COVID-19 Patient Mortality Motley Fool
09:33AM	Gilead Sciences Slides After WHO Study Doubts Remdesivir Effectiveness TheStreet.com
08:02AM	Boeing, Pfizer, Gilead, Covid-19 - 5 Things You Must Know Friday TheStreet.com
07:57AM	Study finds remdesivir, hydroxychloroquine have 'little' impact on mortality in COVID-19 patients MarketWatch
07:28AM	European CHMP Adopts Positive Opinion for Kites KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Business Wire
06:52AM	US STOCKS-Futures perk up on vaccine hopes as stimulus stand-off weighs Reuters
06:35AM	Coronavirus tally: Global cases of COVID-19 38.9 million, 1.09 million deaths and U.S. nears 8 million cases MarketWatch
06:24AM	Analysis: Sales of first big COVID-19 drug, remdesivir, may disappoint Reuters
06:13AM	WHO defends data after concluding Gilead's remdesivir flopped COVID trial Reuters
06:04AM	Analysis: Sales of first big COVID-19 drug, remdesivir, may disappoint Reuters
04:05AM	Gilead's Remdesivir Ineffective In COVID-19 Patients, WHO Study Finds Benzinga
02:10AM	Gilead Sciences Presents Findings from Clinical Studies Evaluating Patients Who Switched to Biktarvy(R) at 2020 Asia Pacific AIDS & Co-infections Conference PR Newswire
Oct-15-20 08:50PM	PRESS DIGEST- Financial Times - Oct. 16 Reuters
05:00PM	Diodes Incorporated to Announce Third Quarter 2020 Financial Results on November 9 Business Wire
04:25PM	Remdesivir didn't reduce mortality among COVID-19 in WHO study: Report MarketWatch
03:56PM	WHO study says remdesivir did not reduce mortality in COVID-19 patients - FT Reuters
09:41AM	Coronavirus second wave looms: 'Hope for the best but prepare for the worst' Yahoo Finance
Oct-14-20 04:44PM	The medical community has learnt a lot and are better prepared for the next phase: doctor Yahoo Finance Video
04:29PM	Coronavirus Latest: Wednesday, October 14 Yahoo Finance Video
04:01PM	Gilead Sciences to Release Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 Business Wire
10:48AM	Eli Lilly's COVID-19 Treatment Candidate Has a Manufacturing Site Problem Motley Fool
10:10AM	Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates Zacks
08:30AM	Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for Immunomedics Tender Offer Business Wire
07:32AM	NIH confirms trial for Lilly antibody treatment is paused MarketWatch
Oct-13-20 05:45PM	Gilead Sciences (GILD) Stock Moves -0.09%: What You Should Know Zacks
04:24PM	Eli Lilly Pauses Covid-19 Treatment Clinical Trials Over Safety Concerns Investor's Business Daily
03:20PM	A study testing Lilly's antibody treatment and remdesivir is paused MarketWatch
03:10PM	Gilead & Galapagos Announce Positive Data on UC Candidate Zacks
12:48PM	NIH to test AbbVie, Boehringer Ingelheim drug in combination with remdesivr MarketWatch
11:29AM	NIH starts clinical trial testing antibody treatments in COVID-19 patients Reuters

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Whitley Richard James	Director	Oct 01	Option Exercise	0.00	1,434	0	31,122	Oct 05 07:09 PM
Parsey Merdad	Chief Medical Officer	Aug 17	Sale	68.32	182	12,434	0	Aug 19 12:53 PM
Mercier Johanna	Chief Commercial Officer	Jul 24	Option Exercise	0.00	7,505	0	7,505	Jul 28 06:47 PM
Rodriguez Javier	Director	Jun 23	Sale	75.50	189	14,270	0	Jun 25 01:51 PM
Dickinson Andrew D	EVP, Chief Financial Officer	Jun 10	Option Exercise	0.00	3,646	0	15,046	Jun 12 03:28 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	May 05	Option Exercise	39.76	13,210	525,225	27,854	May 07 06:02 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	May 05	Sale	79.23	13,210	1,046,640	14,644	May 07 06:02 PM
Cogan John Francis	Director	May 04	Option Exercise	19.63	2,416	47,426	57,276	May 05 04:28 PM
Wilfong Diane E.	SVP, Controller & CAO	May 04	Option Exercise	66.36	11,486	762,211	23,685	May 06 06:40 PM
Wilfong Diane E.	SVP, Controller & CAO	May 04	Sale	80.09	12,264	982,220	11,421	May 06 06:40 PM
Cogan John Francis	Director	May 04	Sale	81.75	2,416	197,508	54,860	May 05 04:28 PM
Cogan John Francis	Director	Apr 27	Option Exercise	19.63	2,413	47,367	57,273	Apr 29 07:28 PM
Cogan John Francis	Director	Apr 27	Sale	79.90	2,413	192,799	54,860	Apr 29 07:28 PM
Cogan John Francis	Director	Apr 20	Option Exercise	19.63	2,413	47,367	57,273	Apr 21 07:42 PM
Cogan John Francis	Director	Apr 20	Sale	83.00	2,413	200,279	54,860	Apr 21 07:42 PM
Cogan John Francis	Director	Apr 13	Option Exercise	19.63	2,413	47,367	57,273	Apr 14 03:52 PM
Cogan John Francis	Director	Apr 13	Sale	75.90	2,413	183,147	54,860	Apr 14 03:52 PM
Cogan John Francis	Director	Apr 06	Option Exercise	19.63	2,413	47,367	57,273	Apr 07 05:34 PM
Cogan John Francis	Director	Apr 06	Sale	79.52	2,413	191,882	54,860	Apr 07 05:34 PM
Cogan John Francis	Director	Mar 30	Option Exercise	19.63	2,413	47,367	57,273	Mar 31 03:00 PM
Cogan John Francis	Director	Mar 30	Sale	75.35	2,413	181,820	54,860	Mar 31 03:00 PM
Cogan John Francis	Director	Mar 23	Option Exercise	19.63	2,413	47,367	57,273	Mar 24 08:42 PM
Cogan John Francis	Director	Mar 23	Sale	75.27	2,413	181,627	54,860	Mar 24 08:42 PM
Cogan John Francis	Director	Mar 16	Option Exercise	19.63	2,413	47,367	57,273	Mar 17 08:01 PM
Cogan John Francis	Director	Mar 16	Sale	67.26	2,413	162,298	54,860	Mar 17 08:01 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Mar 10	Option Exercise	24.30	2,950	71,670	17,594	Mar 12 08:30 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Mar 10	Sale	75.55	2,950	222,873	14,644	Mar 12 08:30 PM
Cogan John Francis	Director	Mar 09	Option Exercise	19.63	2,413	47,367	57,273	Mar 10 09:16 PM
Cogan John Francis	Director	Mar 09	Sale	77.97	2,413	188,142	54,860	Mar 10 09:16 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Mar 02	Sale	70.88	10,441	740,014	14,644	Mar 03 07:40 PM
Lofton Kevin E	Director	Feb 24	Option Exercise	19.63	21,720	426,364	86,579	Feb 25 05:13 PM
WILSON GAYLE E	Director	Feb 10	Option Exercise	19.63	21,720	426,364	148,502	Feb 11 07:02 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 10	Option Exercise	24.30	2,950	71,670	27,640	Feb 12 06:25 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 10	Sale	69.32	2,950	204,494	24,690	Feb 12 06:25 PM
WILSON GAYLE E	Director	Feb 10	Sale	67.72	21,720	1,470,878	126,782	Feb 11 07:02 PM
WOLD OLSEN PER	Director	Feb 07	Option Exercise	20.65	20,282	418,722	118,136	Feb 10 06:25 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 07	Sale	70.00	1,426	99,820	24,690	Feb 10 07:00 PM
WOLD OLSEN PER	Director	Feb 07	Sale	69.00	20,282	1,399,458	97,854	Feb 10 06:25 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 06	Option Exercise	40.56	5,000	202,800	29,690	Feb 10 07:00 PM
WOLD OLSEN PER	Director	Feb 06	Option Exercise	19.63	21,720	426,364	119,574	Feb 10 06:25 PM
WOLD OLSEN PER	Director	Feb 06	Sale	68.12	21,720	1,479,605	97,854	Feb 10 06:25 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 06	Sale	68.18	5,000	340,901	24,690	Feb 10 07:00 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Jan 03	Option Exercise	24.30	2,950	71,670	20,014	Jan 06 07:01 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Jan 03	Sale	64.63	2,950	190,659	17,064	Jan 06 07:01 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Dec 03	Option Exercise	24.30	5,900	143,341	22,964	Dec 04 07:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Dec 03	Sale	65.77	5,900	388,043	17,064	Dec 04 07:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 25	Option Exercise	40.56	15,000	608,400	32,064	Nov 26 02:14 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 25	Sale	66.85	15,000	1,002,809	17,064	Nov 26 02:14 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 19	Option Exercise	24.30	10,000	242,950	27,064	Nov 20 06:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 19	Sale	64.91	10,000	649,062	17,064	Nov 20 06:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 18	Option Exercise	24.30	10,000	242,950	27,064	Nov 20 06:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 18	Sale	63.85	10,000	638,500	17,064	Nov 20 06:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 05	Sale	66.06	2,095	138,404	17,826	Nov 07 08:04 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 01	Option Exercise	16.89	2,400	40,536	23,921	Nov 05 08:21 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 01	Sale	64.52	4,000	258,099	19,921	Nov 05 08:21 PM
Pletcher Brett A	EVP, Gen Counsel & Corp Sec	Oct 28	Sale	63.31	5,677	359,412	21,521	Oct 30 08:35 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience